By using DiabetesTimes.co.uk, you agree to our terms and use of cookies to enhance your experience.

Roche announces new service for ‘easy start’ to insulin therapy

By Editor
19th February 2020
Medical devices

A digital service to support people with type 2 diabetes starting on once-daily long-acting insulin therapy has been presented by Roche Diabetes Care.

RocheDiabetes InsulinStart was unveiled on Tuesday, February 19, on day one of the 13th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in Madrid, Spain. Pilots are currently being conducted to gain user feedback.

RocheDiabetes InsulinStart responds to the needs of people who have to inject long-acting insulin once a day with an easy service that enables a successful start into the unfamiliar therapy. Matthias Koehler of Roche Diabetes Care

Roche say the messaging-based service can provide “true relief” for people with type 2 diabetes, who are at an important turning point in their diabetes journey, and can empower healthcare professionals to take a more personalised approach to diabetes care

The move is part of the company’s drive to improve care and help people to meet their therapy goals by rolling out integrated Personalised Diabetes Management (iPDM), adding to a stable of other digital services, including mySugr and Care Platform.

In December 2019, Roche obtained CE Mark for the service, which cleared the way for pilot projects and studies for evidence generation of the system.

Speaking at the launch event of the service at ATTD, Lisa Huse, Head of Marketing & Customer Experience for Region Europe and North America, said: “Our strategy of integrated personalised diabetes management is designed to find new and different ways for people with diabetes, their caregivers and healthcare professionals to connect and allow different conversations to happen.”

Lisa Huse, from Roche, at ATTD 2020

When oral antidiabetics alone can no longer control blood glucose, adding a fixed amount of complementary long-acting insulin is a preferred therapeutic option. The start of this so-called Basal insulin-supported Oral Therapy (BOT) poses challenges for patients and healthcare professionals alike. The frustration of not being able to manage type 2 diabetes often goes hand-in-hand with the fear of injecting too much or too little insulin.

Many people with diabetes feel overwhelmed adhering to the titration regimens required to optimise treatment. According to studies, less than 40% of people with diabetes reach their glycaemic targets at the end of their insulin adjustment period , and more than 80% of patients are likely to discontinue using insulin in the first year after start . These findings indicate that there is a clear unmet need to optimise titration in clinical practice.

In response, RocheDiabetes InsulinStart promises support during this critical phase. Healthcare professionals enrol their patients to the RocheDiabetes InsulinStart service. The participants are then guided through the process of stepwise increasing their long-acting insulin to reach the individual optimum dosage. Via text message (SMS), they receive a fasting blood glucose testing reminder in the morning and an insulin dose recommendation in the evening

Matthias Koehler, Senior Solutions Development Manager, said: “RocheDiabetes InsulinStart responds to the needs of people who have to inject long-acting insulin once a day with an easy service that enables a successful start into the unfamiliar therapy. It empowers them to confidently and securely manage their therapy adjustments in everyday life.”

The service can also be used by people already on insulin therapy but in need of an adjustment to better control their type 2 diabetes.

The RocheDiabetes InsulinStart service will be offered as an add-on within the Accu-Chek Smart Pix software that provides decision and therapy support at the doctor’s office. The healthcare professional can personalise the insulin adjustment plan to the patient’s needs and can view the patient’s blood glucose results and the amounts of insulin injected at any time during the adjustment phase.

This helps to prevent additional visits to the practice while at the same time clear, actionable support can be provided to make an easy and effective start with long-acting insulin therapy possible. After four to 12 weeks, the participants are usually within their personal target range and can continue with the individually determined, long-acting insulin dose.

Integrated Personalised Diabetes Management (iPDM)

Being a global leader in iPDM, Roche Diabetes Care collaborates with thought leaders around the globe, including people with diabetes, caregivers, healthcare providers and payers. Roche Diabetes Care says it aims to transform and advance care provision and foster sustainable care structures. Under the brands RocheDiabetes, Accu-Chek and mySugr, comprising glucose monitoring, insulin delivery systems and digital solutions, Roche Diabetes Care unites with its partners to create patient-centred value.

By building and collaborating in an open ecosystem, connecting devices and digital solutions as well as contextualise relevant data points, Roche Diabetes Care says it enables deeper insights and a better understanding of the disease, leading to personalised and effective therapy adjustments.

Since 2017, mySugr one of the most popular diabetes management apps is part of Roche Diabetes Care. For more information, please visit www.rochediabetes.com, www.accu-chek.com and www.mysugr.com.

Comments (0)

Register an account or login to comment